Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 706-707

  Pasipanodya, Jotam G ^a   Srivastava, Shashikant ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ISONIAZID; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TUBERCULOSTATIC AGENT; TYROSINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; COMPUTER ANALYSIS; EVIDENCE BASED MEDICINE; GENE; GENE ISOLATION; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT DECISION MAKING; PRIORITY JOURNAL; RPOB GENE; TUBERCULOSIS;

BACTERIAL PROTEINS; DNA, BACTERIAL; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84859716334     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0850     Document Type: Letter

References (5)

1. Williamson D A, Roberts S A, Bower J E, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16: 216-220.
2. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484-1491.
3. Canetti G, Fromans, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-578.
4. van Ingen J, Aarnoutse R, de Vries G, Boeree M J, van Soolingen D. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011; 15: 990-992.
5. Angeby K, Giske C G, Jureen P, Schon T. Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 4492-4493.